Lenvima is an orally administered molecular targeted agent which inhibits the activities of several different molecules including VEGFR, FGFR, RET, KIT and PDGFR. It particularly inhibits VEGFR, FGFR
Conducted by the ECOG-ACRIN Cancer Research Group as part of Exelixis’ collaboration with the US National Cancer Institute (NCI), the Study E1512 is a randomized phase II trial
In CheckMate -017, at one year, Opdivo showed an overall survival rate of 42% versus 24% for docetaxel, with a median overall survival of 9.2 months versus six
The product will be launched under the name Junel Fe 24 (norethindrone acetate and ethinyl estradiol tablets USP and ferrous fumarate tablets) and is currently available in the
MM-398 is a new, stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan. The filing follows the recent submissions of NDA and marketing authorization application (MAA) by its
The trial is designed to evaluate the benefit of Kyprolis administered once-weekly with dexamethasone versus the current FDA-approved twice-weekly administration schedule in patients who have received prior treatment
PARP, or poly (ADP-ribose) polymerase, is a DNA repair protein that restores single strand DNA breaks and by inhibiting PARP, certain cancer cells may be rendered unable to
The data included in the MAA support the use of F/TAF to treat HIV-1 infection in adults in combination with other HIV antiretroviral agents. TAF is a new
In patients with active cancer, the risk of venous thromboembolism (VTE) is four to seven times higher than in people of the same age without cancer, while chemotherapy
Under the multi-year program, the company will award a total of about $3m in grants to investigators in the US. This program is an extension of the company’s
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.